Immunocore HoldingsIMCR +1.11%72 Quick Ratio is 4.15 as of Mar. 2026, which is 5% below its 10-year median of 4.36. GuruFocus rates IMCR with a GF Score™ of 72/100 and a GF Value™ of $46.11 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,413 Biotechnology companies, Immunocore Holdings ranks better than 53.72% on this metric.
Immunocore Holdings has a quick ratio of 4.15. It generally indicates good short-term financial strength.
The historical rank and industry rank for Immunocore Holdings's Quick Ratio or its related term are showing as below:
IMCR'
s Quick Ratio Range Over the Past 10 Years
Min: 1.47 Med: 4.36 Max: 6.31
Current: 4.15
During the past 8 years, Immunocore Holdings's highest Quick Ratio was 6.31. The lowest was 1.47. And the median was 4.36.
IMCR's Quick Ratio is ranked better than 53.72% of 1413
companies
in the Biotechnology industry
Industry Median: 3.6
vs IMCR: 4.15
Immunocore Holdings (NAS:IMCR) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Immunocore Holdings Quick Ratio Related Terms
Immunocore Holdings Quick Ratio Historical Data
* Premium members only.
The historical data trend for Immunocore Holdings's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Immunocore Holdings's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunocore Holdings Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immunocore Holdings's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Immunocore Holdings's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Immunocore Holdings's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunocore Holdings (IMCR) has a Quick Ratio of 4.15 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Immunocore Holdings and its competitors. This is near median its historical median of 4.36. Over the past decade, Immunocore Holdings' Quick Ratio has ranged from 1.47 to 6.31. According to the industry distribution chart, Immunocore Holdings ranks #654 out of 1413 companies in the Biotechnology industry, placing it in the top 46.3%.
Is Immunocore Holdings' Quick Ratio too high?
Immunocore Holdings' current Quick Ratio of 4.15 is near median its 10-year median of 4.36. Over the past 10 years, this metric has ranged from a low of 1.47 to a high of 6.31. The Biotechnology industry median Quick Ratio is 3.60. Immunocore Holdings' value of 4.15 is 15.3% above this industry median. Based on the distribution chart, Immunocore Holdings ranks #654 out of 1413 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Immunocore Holdings has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Immunocore Holdings' Quick Ratio compare to MAZE and FTRE?
According to the Biotechnology industry distribution chart, Immunocore Holdings ranks #654 out of 1413 companies for Quick Ratio. This puts Immunocore Holdings in the upper half of its industry. The industry median Quick Ratio is 3.60. Immunocore Holdings' value of 4.15 is 15.3% above this benchmark. Historically, Immunocore Holdings' own Quick Ratio has ranged from 1.47 to 6.31 over the past decade. While the company's 10-year median is 4.36 vs. the industry median of 3.60, Immunocore Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immunocore Holdings's current Quick Ratio of 4.15 is 15.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Immunocore Holdings and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunocore Holdings's current Quick Ratio is 4.15, which is near median its own 10-year median of 4.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunocore Holdings stock overvalued right now?
Based on GuruFocus' analysis, Immunocore Holdings (IMCR) is currently considered Possible Value Trap. The stock's GF Value™ is $46.11, compared to a current price of $30.87 — trading 33.1% below its estimated fair value. The current Quick Ratio is 4.15, which is near median its 10-year median of 4.36 and 15.3% above the Biotechnology industry median of 3.60. Immunocore Holdings' overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Immunocore Holdings (IMCR), the current Quick Ratio is 4.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immunocore Holdings (IMCR) Overvalued in 2026?
Based on GuruFocus' analysis, Immunocore Holdings stock appears to be undervalued.
The current stock price of $30.87 is trading 33.1% below its estimated GF Value™ of $46.11.
GuruFocus considers Immunocore Holdings to be Possible Value Trap.
Key valuation signals for IMCR:
Quick Ratio: 4.15 (near median its 10-year median of 4.36)
GF Value™: $46.11 vs. price of $30.87 (33.1% below fair value)
Industry Position: 15.3% above the Biotechnology median (#654 of 1413)
No single metric tells the full story. See the IMCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
72GF Score
Get the complete analysis for IMCR
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMCR has been successfully added to your 
